SARS-CoV-2 does not just attack the lungs. The virus directly infects cells lining the small intestine, and that infection is the primary reason so many people develop diarrhea during or after COVID-19. In one U.S. multicenter study, about a third of hospitalized patients reported diarrhea on arrival, and gut symptoms were actually the first sign of illness for roughly one in seven people. The story gets more complicated when you factor in lingering viral material in the gut, microbiome disruption, and the emergence of new digestive disorders weeks or months after the initial infection.
How the Virus Gets Into the Gut
The same receptor SARS-CoV-2 uses to enter lung cells, called ACE2, is also found in high concentrations on the surface of mature enterocytes, the absorptive cells that line the small intestine. Researchers confirmed early in the pandemic that the virus could productively infect these gut cells, meaning it doesn’t just pass through but actually enters, replicates, and damages them.1PubMed Central. SARS-CoV-2 productively infects human gut enterocytes Two additional proteins on the intestinal surface, TMPRSS2 and TMPRSS4, help the virus fuse with host cells, essentially giving it a second set of keys to get inside.2PubMed Central. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
Once inside, the virus damages intestinal cells and triggers a cascade of problems. Viral entry leads to a downregulation of the ACE2 receptors themselves, which impairs the gut’s barrier function. Think of the intestinal lining as a tightly sealed wall: when that seal weakens, fluid and immune signals leak where they shouldn’t, producing inflammation and watery stools.3PubMed Central. Pathophysiological mechanisms underlying gastrointestinal symptoms in patients with COVID-19 Interferon signaling, part of your body’s antiviral defense, also becomes imbalanced in infected intestinal tissue, compounding the damage to the gut lining.4PubMed Central. SARS-CoV-2 infection causes intestinal cell damage: Role of interferon’s imbalance
How Common Diarrhea Is During Acute COVID
Estimates vary depending on how the studies were done, who was included, and whether researchers asked patients about symptoms versus waiting for patients to volunteer them. A large meta-analysis pooling data from thousands of patients across dozens of studies found that about 7 to 8 percent of people with confirmed COVID reported diarrhea.5JAMA Network Open. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis But when researchers actively asked about gut symptoms in a U.S. multicenter cohort, rates were far higher: roughly 61 percent reported at least one gastrointestinal symptom, with diarrhea specifically occurring in about 34 percent.6PubMed Central. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study
That gap likely reflects underreporting. Early pandemic studies, especially those from China, focused heavily on respiratory symptoms and didn’t always prompt for GI complaints. A multicenter study in Hubei, for instance, found diarrhea in about 34 percent of those with digestive symptoms, but overall GI-specific symptoms (excluding the more vague loss of appetite) were noted in about 19 percent of patients.7PubMed Central. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study That same study found something worth noting: patients who had digestive symptoms tended to take longer to seek medical care and, as illness severity increased, the digestive symptoms became more pronounced.
A practical takeaway here is that diarrhea during COVID is common enough that it shouldn’t be dismissed as unrelated. In a small but real percentage of cases, gut symptoms appear before any cough or fever, which historically meant some people didn’t suspect COVID at all.
The Virus Lingers in the Gut Much Longer Than in the Throat
One of the more unsettling findings from the past few years is that SARS-CoV-2 genetic material sticks around in the gastrointestinal tract long after it has cleared from the respiratory system. A meta-analysis found that viral RNA shedding in stool lasted an average of about 22 days, compared with roughly 15 days in respiratory samples, a lag of about a week.8PubMed Central. Prevalence and Persistent Shedding of Fecal SARS-CoV-2 RNA in Patients With COVID-19 Infection: A Systematic Review and Meta-analysis But that average hides much more dramatic outliers.
A longitudinal study that followed patients over months found that at four months after diagnosis, while everyone had cleared the virus from their throat, about 13 percent were still shedding viral RNA in their stool. Even at seven months, close to 4 percent of participants still had detectable viral RNA in fecal samples.9PubMed Central. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection The researchers also found that ongoing GI symptoms like abdominal pain, nausea, and vomiting were associated with this persistent fecal shedding.10Med. Dynamics and spatial-temporal characteristics of SARS-CoV-2 RNA persistence in the gastrointestinal tract of patients with COVID-19
Detecting viral RNA doesn’t necessarily mean someone is shedding live, infectious virus. But the finding raises questions about whether the gut serves as a kind of reservoir where viral components persist and potentially contribute to ongoing symptoms. It also has implications for wastewater surveillance programs that monitor sewage for SARS-CoV-2 as a community health signal.
What Happens to Your Gut Bacteria
COVID-19 reshapes the community of microbes living in your intestines, and those changes can outlast the acute infection. Studies consistently show a drop in beneficial bacteria, particularly species like Faecalibacterium prausnitzii and Bifidobacterium, alongside an increase in opportunistic pathogens such as Enterococcus and E. coli.11Frontiers in Cellular and Infection Microbiology. Microbiome dysbiosis in SARS-CoV-2 infection: implication for pathophysiology and management strategies of COVID-19 Animal models have confirmed this pattern: mice infected with SARS-CoV-2 developed significant losses of certain beneficial anaerobic bacteria and increases in potentially harmful Proteobacteria, driven largely by a surge in Escherichia/Shigella species.12Nature Communications. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
This microbial imbalance feeds into the diarrhea problem in at least two ways. First, the decline in beneficial bacteria weakens the intestinal barrier further, since many of those organisms produce short-chain fatty acids that help maintain the gut lining. Second, the bloom of pathogenic species can trigger additional inflammation and fluid secretion. Antibiotics used to treat secondary infections in hospitalized COVID patients can deepen these imbalances, creating a cycle of disruption that takes time to resolve.13PubMed Central. Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
When Diarrhea Keeps Going After Recovery
For most people, COVID-related diarrhea resolves within a week or two. But a meaningful fraction develop new, persistent digestive problems that meet the criteria for functional gastrointestinal disorders, conditions where the gut misbehaves without an obvious structural cause. A prospective follow-up study found that about 11 percent of COVID patients developed functional GI symptoms within the first month, with about 7 percent still affected at six months. None of the healthy controls in the same study developed these conditions.14Clinical Gastroenterology and Hepatology. Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study The most common diagnosis in these patients was irritable bowel syndrome, followed by functional diarrhea and functional dyspepsia.
Another study comparing COVID patients to controls at six months found that people who had COVID were significantly more likely to have developed IBS: about 3.2 percent compared to 0.5 percent of controls.15PubMed. Post COVID-19 irritable bowel syndrome These numbers may sound small in isolation, but they represent a large number of people worldwide given how many COVID infections have occurred. Researchers have found that having GI symptoms during the acute illness is an independent risk factor for developing these longer-term functional disorders, so your chances are higher if diarrhea was part of your initial COVID experience.
The mechanism behind this persistence is still being worked out, but two leading candidates are lingering viral material and ongoing immune activation. A study using tissue biopsies from people with long COVID symptoms found SARS-CoV-2 RNA in the lining of the lower intestine up to 676 days after the original infection.16PubMed Central. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection Whether this represents ongoing low-level viral replication or just leftover fragments isn’t fully settled, but the fact that T cells in these tissues remained activated suggests the immune system is still responding to something.17PubMed Central. Mechanisms of Gut-Related Viral Persistence in Long COVID The disrupted gut microbiome and compromised barrier integrity may also feed into a broader cycle involving the gut-brain axis, potentially explaining why some long COVID patients experience both GI distress and neurological symptoms like brain fog or mood changes.18PubMed Central. The Intestine in Acute and Long COVID: Pathophysiological Insights and Key Lessons
What You Can Actually Do About It
Managing diarrhea during or after COVID starts with the basics. Staying hydrated matters more than anything else, particularly for older adults and children who dehydrate faster. Oral rehydration solutions are more effective than plain water when diarrhea is frequent, because they replace lost electrolytes along with fluids. Bland, easy-to-digest foods tend to be better tolerated during the acute phase.
There is growing interest in using probiotics, prebiotics, and related gut-targeted therapies for COVID-related diarrhea. Clinical evidence indicates that probiotics can reduce the duration and severity of GI symptoms during acute infection and may help restore the microbial balance that COVID disrupts.19Life Sciences. The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review For longer-term post-COVID gut complaints, clinical trials have shown that modulating the gut microbiome through probiotics, prebiotics, or even fecal microbiota transplantation led to improvements in multiple symptoms, including gastrointestinal distress, fatigue, and concentration difficulties.20PubMed Central. Long COVID and gut microbiome: insights into pathogenesis and therapeutics The evidence is encouraging but still accumulating; there isn’t yet a single probiotic strain or protocol that’s established as the standard approach for post-COVID GI symptoms.21PubMed Central. Exploring the Interplay between COVID-19 and Gut Health: The Potential Role of Prebiotics and Probiotics in Immune Support
Zinc supplementation has some supporting evidence, particularly for shortening diarrhea episodes. A review noted that zinc reduced the average duration of childhood diarrhea by about 20 percent, and guidelines recommend 20 mg per day for children over six months during acute diarrhea episodes.22Oxford Academic (Nutrition Reviews). Therapeutic supplementation with zinc in the management of COVID-19–related diarrhea and ageusia/dysgeusia: mechanisms and clues for a personalized dosage regimen Whether zinc offers the same benefit for COVID-specific diarrhea in adults is less clear, but given its general safety profile and its role in immune function, it is a reasonable consideration to discuss with a healthcare provider.
One word of caution about anti-diarrheal medications like loperamide: while commonly used for everyday diarrhea, their use in COVID-associated diarrhea warrants more care. Because SARS-CoV-2 actively replicates in the GI tract, slowing gut motility could theoretically prolong viral clearance from the intestines or worsen systemic inflammation. Clinicians are advised to weigh risks and benefits carefully and rule out bacterial co-infections before prescribing these agents.23PubMed Central. The use of antimotility drugs in COVID-19 associated diarrhea
If You Have Inflammatory Bowel Disease
People living with Crohn’s disease or ulcerative colitis understandably worry about what COVID-19 might do to their already-compromised gut. The evidence offers some reassurance alongside some real risks. Large nationwide data show that people with inflammatory bowel disease don’t appear to catch COVID at higher rates than the general population.24Journal of Crohn’s and Colitis. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study However, once infected, outcomes can be worse. An analysis of nationwide inpatient data found that hospitalized patients with both IBD and COVID had higher mortality, longer hospital stays, and more frequent need for intensive care and mechanical ventilation compared to hospitalized COVID patients without IBD.25PubMed Central. Predictors of Hospital-related Outcomes of COVID-19 Infection in Patients With Inflammatory Bowel Disease in the Early Pandemic Phase: A Nationwide Inpatient Database Survey
Age over 55, existing comorbidities, active IBD at the time of infection, and systemic corticosteroid use have all been identified as factors associated with more severe COVID outcomes in people with IBD.26PubMed Central. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease About 10 percent of IBD patients in one study experienced a flare of their bowel disease within three months of their COVID infection. The practical message: if you have IBD, staying current on vaccination and working with your gastroenterologist to keep disease activity controlled are the most important steps you can take.
GI Symptoms in Children and MIS-C
Children generally experience milder COVID than adults, but their gut symptoms can be surprisingly prominent and, in rare cases, signal something more serious. In multisystem inflammatory syndrome in children, known as MIS-C, a post-infectious inflammatory condition that usually appears two to six weeks after COVID, gastrointestinal symptoms are among the most common features. A systematic review found that roughly 71 percent of children with MIS-C had GI symptoms, with diarrhea occurring in about 27 percent and abdominal pain in about 34 percent.27Paediatric Respiratory Reviews. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation
What makes this tricky is that the abdominal pain in MIS-C can mimic appendicitis or other surgical emergencies, sometimes leading to unnecessary imaging or even exploratory procedures before the diagnosis is recognized. A large study of children with SARS-CoV-2 infection or MIS-C found that diarrhea in these patients was associated with a higher chance of inflammation around the mesenteric lymph nodes and abdominal fluid collections.28JAMA Network Open. Factors Associated With Severe Gastrointestinal Diagnoses in Children With SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome For parents, the key thing to watch for is a child who develops persistent abdominal pain, diarrhea, fever, and rash a few weeks after a known or suspected COVID infection, as that combination should prompt urgent medical evaluation.
When to Seek Medical Attention
Mild diarrhea that resolves within a few days of a COVID infection usually doesn’t require anything beyond hydration and rest. But there are situations where you should talk to a doctor. Diarrhea lasting more than a week, blood in the stool, signs of dehydration like dark urine or dizziness, high fever alongside the diarrhea, or significant weight loss are all reasons to seek care. If new bowel symptoms develop weeks or months after you’ve otherwise recovered from COVID, that pattern is worth bringing up with a healthcare provider. As noted, a meaningful number of people develop new functional GI disorders after COVID, and getting an accurate diagnosis early can help guide management, whether that means dietary changes, targeted probiotics, or medications to address motility problems.
Prospective follow-up data suggest that having GI symptoms during the initial COVID illness is itself a risk factor for developing these post-infection functional disorders at six months, and the rate of these disorders among COVID patients was nearly three times that of healthy controls.29PubMed Central / BioMed Central. Post-infection functional gastrointestinal disorders following coronavirus disease-19: a prospective follow-up cohort study The concept of post-infectious gut dysfunction is not new to COVID; it has been well-documented after infections with bacteria like Salmonella and Campylobacter for decades. COVID appears to be another pathogen that can trigger the same syndrome, and awareness of this possibility helps both patients and clinicians avoid lengthy diagnostic detours looking for causes that aren’t there.